Tracks side effects of targeted drugs in people with pulmonary hypertension
Follows people with pulmonary hypertension taking targeted drugs, recording side effects and deaths.
Plain-language title generated from the registry record
Registry title: Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Fuwai Hospital Chinese Academy of Medical SciencesBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT05372263
- Record updated
- 4 December 2025
- Original description
Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.Read full original descriptionShow less
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.
Inclusion: Age from 3 months to 85 years, no sex preference; Right heart catheter meet the following conditions simultaneously: mPAP≥25mmHg, and PVR > 3 Wood units(in children PVRi > 3 WU x m2), and PAWP≤15 mmHg at rest; Patients diagnosed with group 1,2,4,5 PH according to the WHO classification, detailed description is as follows: Pulmonary arterial hypertension, Lung disease / chronic hypoxia associated pulmonary hypertension, Pulmonary hypertension associated with pulmonary artery stenosis / obstruction and Pulmonary hypertension caused by other multiple factors; Take at least one pulmonary hypertension targeted drug or calcium antagonist; Signed written informed consent.
Exclusion: Patients diagnosed with pulmonary hypertension related to left heart disease.